Similar articles for PMID: 25902479

Year	Number of Results
2001	1
2002	3
2003	1
2004	3
2005	2
2006	2
2007	4
2008	4
2009	6
2010	5
2011	3
2012	7
2013	4
2014	8
2015	13
2016	4
2017	3
2018	5
2019	2
2020	1
2021	1
2022	1
2024	0

1

Distinct mechanisms of tumor resistance to NK killing: of mice and men.

Pardoll DM. Pardoll DM. Immunity. 2015 Apr 21;42(4):605-6. doi: 10.1016/j.immuni.2015.04.007. Immunity. 2015. PMID: 25902479 Free PMC article.

2

Shed NKG2D ligand boosts NK cell immunity.

Narni-Mancinelli E, Vivier E. Narni-Mancinelli E, et al. Cell Res. 2015 Jun;25(6):651-2. doi: 10.1038/cr.2015.41. Epub 2015 Apr 7. Cell Res. 2015. PMID: 25849247 Free PMC article.

3

Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.

Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet DH. Deng W, et al. Science. 2015 Apr 3;348(6230):136-9. doi: 10.1126/science.1258867. Epub 2015 Mar 5. Science. 2015. PMID: 25745066 Free PMC article.

4

Immunotherapy: Soluble ligands--a new approach to cancer therapy.

Errico A. Errico A. Nat Rev Clin Oncol. 2015 Jun;12(6):311. doi: 10.1038/nrclinonc.2015.60. Epub 2015 Mar 24. Nat Rev Clin Oncol. 2015. PMID: 25801813 No abstract available.

5

Immunology. MULT1plying cancer immunity.

Steinle A, Cerwenka A. Steinle A, et al. Science. 2015 Apr 3;348(6230):45-6. doi: 10.1126/science.aaa9842. Science. 2015. PMID: 25838370 No abstract available.

6

New twist on the regulation of NKG2D ligand expression.

Cerwenka A. Cerwenka A. J Exp Med. 2009 Feb 16;206(2):265-8. doi: 10.1084/jem.20090225. Epub 2009 Feb 9. J Exp Med. 2009. PMID: 19204110 Free PMC article.

7

A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.

Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. Diefenbach A, et al. Eur J Immunol. 2003 Feb;33(2):381-91. doi: 10.1002/immu.200310012. Eur J Immunol. 2003. PMID: 12645935 Free article.

8

Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.

Belting L, Hömberg N, Przewoznik M, Brenner C, Riedel T, Flatley A, Polić B, Busch DH, Röcken M, Mocikat R. Belting L, et al. Eur J Immunol. 2015 Sep;45(9):2593-601. doi: 10.1002/eji.201445375. Epub 2015 Jul 7. Eur J Immunol. 2015. PMID: 26151313 Free article.

9

Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.

Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A. Pende D, et al. Cancer Res. 2002 Nov 1;62(21):6178-86. Cancer Res. 2002. PMID: 12414645

10

A dual function of NKG2D ligands in NK-cell activation.

Cheney EE, Wise EL, Bui JD, Schreiber RD, Carayannopoulos LN, Spitzer D, Zafirova B, Polic B, Shaw AS, Markiewicz MA. Cheney EE, et al. Eur J Immunol. 2012 Sep;42(9):2452-8. doi: 10.1002/eji.201141849. Epub 2012 Jul 27. Eur J Immunol. 2012. PMID: 22740149 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

80 results

Results by year